Calidi Biotherapeutics Unveils Promising Data on CLD-401 at ASCO 2025
TL;DR
Calidi Biotherapeutics' CLD-401 offers a competitive edge in immuno-oncology with its novel CD55 receptor modification, enhancing resistance to immune clearance for systemic cancer therapy.
Calidi Biotherapeutics advances its RedTail platform with CLD-401, incorporating a chimeric CD55 receptor to shield the virus from immune system clearance, detailed in ASCO presentation.
Calidi Biotherapeutics' innovative CLD-401 therapy promises to improve cancer treatment outcomes, offering hope for patients with high unmet medical needs through targeted immunotherapy.
Discover how Calidi Biotherapeutics is revolutionizing cancer treatment with CLD-401, a therapy designed to evade the immune system and target tumors more effectively.
Found this article helpful?
Share it with your network and spread the knowledge!
Calidi Biotherapeutics Inc. (NYSE American: CLDI) has taken a significant step forward in the fight against cancer with the presentation of promising new data on its lead candidate, CLD-401, at the American Society of Clinical Oncology (ASCO) Annual Meeting. The data highlights a novel genetic modification that enhances the virus's resistance to immune clearance, a breakthrough that could revolutionize systemic delivery methods for oncolytic virus therapies.
The development of CLD-401, part of Calidi's RedTail platform, represents a pivotal advancement in immuno-oncology. By incorporating a chimeric CD55 receptor into the virus's envelope, Calidi has significantly improved the therapy's ability to evade the humoral immune system. This innovation not only underscores the potential of CLD-401 to target metastatic cancers more effectively but also opens new avenues for treating non-small cell lung cancer, ovarian cancer, and other tumors with high unmet medical needs.
The implications of this announcement are profound for patients, healthcare providers, and the biotechnology industry. With cancer remaining a leading cause of death worldwide, the need for innovative treatments that can target and destroy cancer cells without harming healthy tissue is critical. Calidi's advancements in enveloped oncolytic virus technology could pave the way for more effective and less invasive cancer therapies, offering hope to millions of patients battling this devastating disease.
Curated from InvestorBrandNetwork (IBN)
